Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
Delayed Quote. Delayed Nasdaq - 09/27 04:00:00 pm
307.09 USD   -7.91%
04:43pPfizer begins study of mRNA flu vaccine
RE
04:36pPfizer begins study of mRNA flu vaccine
RE
11:10aGLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Pfizer and BioNTech Announce -3-

07/21/2021 | 07:15am EDT

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

BioNTech Forward-looking Statements

This press release contains "forward-looking statements" of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech's efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential second booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.

For a discussion of these and other risks and uncertainties, see BioNTech's Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC's website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

About Biovac

Biovac was established in 2003 to revive local human vaccine production in Southern Africa. Alongside the development of the local vaccine industry, through steep investment in local skills and modern facilities, the company has secured high profile technology transfers from international pharmaceutical companies incuding Pfizer and Sanofi Pasteur for the manufacturing of paediatric vaccines. The company currently supplies a comprehensive range of vaccines in support of the South African Department of Health's Expanded Programme for Immunisation. In addition to supplying millions of doses of vaccines per year, across South Africa and into some neighbouring countries, Biovac has been distributing COVID19 vaccines in South Africa under various temperature conditions, including minus 70degrees, minus 20 degrees and between 2 and 8 degrees. For more information, please visit: https://www.globenewswire.com/Tracker?data=NsUlWKv3AxJMJxFySO3OqpbX0CvJUGFdmNbUnPHYJWuJDQngcbqDXh_l2CYI8bPfzXLNadyFaHszaE770joaoHyq4cIldrEFjPb-YUKxvlI= www.biovac.co.za, our LinkedIn page and our Facebook page @biovacSA.

Pfizer Contacts:

Media Relations

Amy Rose

+1 (212) 733-7410

https://www.globenewswire.com/Tracker?data=_uG-yUy9lsuv_yJyuvfoakS8mBeOEZTr2WPPhrcJ3kCMBSAMTcXcvoosK257bD_FietOFWoKM3uId-Lhy7HL9QUXEFclDhTItHdNkyVHyN4= Amy.Rose@pfizer.com

Investor Relations

Chuck Triano

+1 (212) 733-3901

https://www.globenewswire.com/Tracker?data=vE0e9_KANM1zFj2f8P2TGIPdBmj8PW6jN31dCXAC6oVUVjQWU131arku6zjMECQgHls2Q_M-RwWrX6IVOSLZcMT5T95o4VgFvxObd3GVsM0GfXNbrqmqvJ3k916_SAr9 Charles.E.Triano@Pfizer.com

BioNTech Contacts:

Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513

https://www.globenewswire.com/Tracker?data=enQ_-RhbHOt5ZTWbCcAqXWUqlLYbTmUSVRdnw3QssLOYOmrPZgsjYPahjiEzDkyYJZ5xgkVZmooVcL2QhA8HXxO_iLgRU_32XbnkTfd54dM= Media@biontech.de

Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

https://www.globenewswire.com/Tracker?data=Q0hCR_yqHidYdjTfRHjsE2d6RmqTB572y_pi1j-RGe3Ntx0jBJt0lajrOnORJ7OERXfDjpkJ_rFGGS2NcGSPe4-iAbQmeP463kJRMbXwDfQ= Investors@biontech.de

Biovac Contacts:

Media Relations

Michelle Viljoen

+27 21 514 5000

https://www.globenewswire.com/Tracker?data=DRu1Lbm2cI9Klje5yWoogvS7a-r8QxnIi3sIvLQVX1CZ3d39inSFPssFVsXU8Xcgxe8aVeX2fPNUzIc9H--5Hr4vXcRvdDzRwx7I0sMmZ_Y= media@biovac.co.za

(END) Dow Jones Newswires

July 21, 2021 07:15 ET (11:15 GMT)

All news about BIONTECH SE
04:43pPfizer begins study of mRNA flu vaccine
RE
04:36pPfizer begins study of mRNA flu vaccine
RE
11:10aGLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
11:01aEuropean ADRs Move Higher in Monday Trading
MT
09:30aWALL STREET STOCK EXCHANGE : A new gift from China
08:00aUNIVERSITY OF PENNSYLVANIA : Drew Weissman and Katalin Kariko receive 2021 Lasker Award
AQ
09/26THE LATEST : CDC head acknowledges confusion over boosters
AQ
09/24ADRs End Lower; WPP, BioNTech Among Companies Actively Trading
DJ
09/24Equities Fluctuate Midday as Real Estate, Tech Among Worst Performers
MT
09/24WALGREENS BOOTS ALLIANCE : Who can get a COVID-19 vaccine booster in the United States?
RE
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 16 863 M 19 721 M 19 721 M
Net income 2021 8 881 M 10 386 M 10 386 M
Net cash 2021 9 100 M 10 642 M 10 642 M
P/E ratio 2021 8,66x
Yield 2021 -
Capitalization 74 169 M 74 169 M 86 740 M
EV / Sales 2021 3,86x
EV / Sales 2022 3,11x
Nbr of Employees 2 500
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 307,09 €
Average target price 279,55 €
Spread / Average Target -8,97%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE309.08%80 542
GILEAD SCIENCES, INC.22.19%89 259
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.31%47 634
BEIGENE, LTD.46.88%35 310